Related Experiment Video
Updated: Jun 23, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention
Arijit Dasgupta1, Debabrata Mukherjee
1Gill Heart Institute, University of Kentucky, Lexington, KY 40536-0200, USA.
Insights
Clopidogrel effectively reduces periprocedural myocardial infarction after percutaneous coronary intervention (PCI). Optimal dosing involves a 600 mg loading dose given 2-6 hours before PCI for enhanced efficacy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Periprocedural myocardial infarction (MI) is common after percutaneous coronary intervention (PCI), affecting up to 25% of patients with creatinine kinase elevations and 50% with troponin elevations.
- Periprocedural MI is linked to adverse short-, intermediate-, and long-term outcomes, including increased mortality.
Purpose of the Study:
- To review the role of clopidogrel in mitigating periprocedural myonecrosis following PCI.
- To assess clopidogrel's efficacy in reducing myocardial infarction as measured by cardiac biomarkers and ischemic events.
Main Methods:
- Review of existing data and clinical evidence on clopidogrel's use in PCI.
- Analysis of different clopidogrel dosing strategies and their impact on post-procedural cardiac events.
Main Results:
- Clopidogrel is a key agent for reducing post-PCI myocardial infarction.
- A loading dose of 600 mg administered 2-6 hours prior to PCI appears more effective than 300 mg given 6-15 hours prior.
- The benefits of clopidogrel are independent and additive to other antiplatelet/antithrombotic therapies.
Conclusions:
- Clopidogrel plays a significant role in reducing periprocedural myonecrosis and associated adverse outcomes after PCI.
- Optimizing clopidogrel loading dose and timing can enhance its protective effects against post-PCI myocardial infarction.
Abstract:
It is estimated that approximately a quarter of patients undergoing coronary intervention may have significant post-procedural creatinine (CK)/creatinine kinase myocardial band (CK-MB) elevations and approximately half may have post-procedural troponin elevations. Current data suggest that periprocedural infarction is associated with short-, intermediate-, and long-term adverse outcomes, most notably mortality. This review examines the role of clopidogrel in decreasing periprocedural myonecrosis following percutaneous coronary intervention (PCI). Clopidogrel is an important pharmacologic agent used to reduce myocardial infarction post-coronary intervention as assessed directly by the evaluation of cardiac biomarkers and indirectly by the evaluation of short-term ischemic events. The optimal dose of clopidogrel is considered to be at least 300 mg given 6 to 15 hours prior to PCI but there is considerable evidence to suggest that a loading dose of 600 mg given 2 to 6 hours prior to PCI may be more efficacious in limiting post-coronary intervention events. The benefit obtained from clopidogrel appears independent of and incremental to that of other antiplatelet and antithrombotic agents used during and after coronary intervention.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Angina IV: Management
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins